A pharmaceutical co-formulation comprising a calcitonin mimetic and an insulin sensitiser, and its use in the treatment type I diabetes, type II diabetes or a metabolic syndrome, or for reducing an undesirably high fasting serum glucose level, or for reducing an undesirably high peak serum glucose level, or for reducing an undesirably high peak serum insulin level, or for reducing an undesirably large response to a glucose tolerance test.
